RAPT Stock Summary and Trading Ideas (Rapt Therapeutics | NASDAQ:RAPT)

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Rapt Therapeutics trades on the NASDAQ stock market under the symbol RAPT.

As of January 17, 2025, RAPT stock price climbed to $1.20 with 837,433 million shares trading.

RAPT has a market cap of $41.95 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, RAPT traded as high as $32.45 and as low as $.79.

The top ETF exchange traded funds that RAPT belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

RAPT has underperformed the market in the last year with a price return of -95.1% while the SPY ETF gained +28.0%. RAPT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -29.0% and -28.1%, respectively, while the SPY returned +3.0% and +1.0%, respectively.

RAPT support price is $1.09 and resistance is $1.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RAPT shares will trade within this expected range on the day.